Barron's: Stock buy, dividend hike could boost Pfizer

A big stock buyback or an increased dividend could lift Pfizer shares to $25 over the next year, and the retirement of former CEO Jeff Kindler also gives Pfizer an opportunity to shed assets, Barron's said. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.